| scholarly article | Q13442814 |
| P50 | author | Ted Baker | Q18097437 |
| Genevieve Evans | Q42836726 | ||
| Shaun Lott | Q58306268 | ||
| P2093 | author name string | Alexandra Manos-Turvey | |
| Jodie M Johnston | |||
| Richard J Payne | |||
| Esther M M Bulloch | |||
| Gamma Chi | |||
| Patrick D O'Connor | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| salicylic acid | Q193572 | ||
| P304 | page(s) | 4868-4879 | |
| P577 | publication date | 2012-06-07 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Implications of binding mode and active site flexibility for inhibitor potency against the salicylate synthase from Mycobacterium tuberculosis | |
| P478 | volume | 51 |
| Q41585809 | A new salicylate synthase AmS is identified for siderophores biosynthesis in Amycolatopsis methanolica 239(T). |
| Q28829605 | An Open and Shut Case: The Interaction of Magnesium with MST Enzymes |
| Q35688927 | Breaking a pathogen's iron will: Inhibiting siderophore production as an antimicrobial strategy |
| Q34622456 | Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. |
| Q89597711 | In Silico Strategies in Tuberculosis Drug Discovery |
| Q37199670 | Lysine221 is the general base residue of the isochorismate synthase from Pseudomonas aeruginosa (PchA) in a reaction that is diffusion limited |
| Q49893928 | Nonribosomal peptides for iron acquisition: pyochelin biosynthesis as a case study. |
| Q37264871 | Small-molecule inhibitor of the Shigella flexneri master virulence regulator VirF. |
| Q36341884 | Stereocontrolled Synthesis of a Potential Transition-State Inhibitor of the Salicylate Synthase MbtI from Mycobacterium tuberculosis |
| Q27702561 | Structure and inhibition of subunit I of the anthranilate synthase complex of Mycobacterium tuberculosis and expression of the active complex |
| Q34459862 | Synthesis and evaluation of M. tuberculosis salicylate synthase (MbtI) inhibitors designed to probe plasticity in the active site. |
| Q27697678 | Tracing binding modes in hit-to-lead optimization: chameleon-like poses of aspartic protease inhibitors |
| Q88158454 | Unraveling the Structure and Mechanism of the MST(ery) Enzymes |
| Q48145820 | When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode? |
| Q58378507 | When Inhibitors Do Not Inhibit: Critical Evaluation of Rational Drug Design Targeting Chorismate Mutase fromMycobacterium tuberculosis |
Search more.